In the US, Dupilumab (dupilumab systemic) is a member of the drug class interleukin inhibitors and is used to treat Asthma - Maintenance, Atopic Dermatitis, Chronic Rhinosinusitis with Nasal Polyps and Eczema.
CAS registry number (Chemical Abstracts Service)
Immunoglobulin, anti-(human interleukin 4 receptor α) (human REGN668 heavy chain), disulfide with human REGN668 κ-chain, dimer (USAN)
- Dupilumabum (Latin)
- Dupilumab (German)
- Dupilumab (French)
- Dupilumab (Spanish)
- Dupilumab (OS: JAN)
- REGN 668 (Stoffliste) (IS)
- SAR 231893 (Stoffliste) (IS)
- UNII-420K487FSG (ChemID) (IS)
Regeneron, United States; Sanofi, Denmark; Sanofi, Ireland; Sanofi Oy, Finland; Sanofi-Aventis, Australia; Sanofi-Aventis, Netherlands; Sanofi-Aventis, Norway; Sanofi-Aventis, Poland
|JAN||Japanese Accepted Name|
|Rec.INN||Recommended International Nonproprietary Name (World Health Organization)|
|USAN||United States Adopted Name|
Further information on drug naming conventions: International Nonproprietary Names.
Important Notice: The Drugs.com international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.